Cytosine deaminase expressing human mesenchymal stem cells mediated tumour regression in melanoma bearing mice

Abstract

CD y-AT-MSC capability of targeting subcutaneous melanoma offers a possibility to selectively produce cytotoxic agent in situ. Our data further demonstrate beneficial biological properties of AT-MSC as a cellular vehicle for enzyme/prodrug therapy approach to molecular chemotherapy.